Arrow Generics UK has launched generic versions of AstraZeneca’s Zomig (Zolmitriptan) and Zomig Rapimelt (Zolmitriptan Orodispersible) in the UK and France.
Arrow, part of the Watson Group, released the generics after the patent expired for the two treatments indicated for patients with migraine headache with or without aura.
Last year, the two treatments had sales in the UK and France of around $107 million in the two markets, according to IMS Health data.
The two generics are also set to be launched in the Nordic region later this month on the date of expiry.
Joining Zolmitriptan and Zolmitriptan Orodispersible, Arrow has also launched a generic alternative of GSK’s Naramig (Naratriptan) – indicated for the same condition.